P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer

Current Medicinal Chemistry

Volumn 21, Issue 4, 2014, Pages 501-510

  Donnelly, S M ^a   Paplomata, E ^a   Peake, B M ^b   Sanabria, E ^b   Chen, Z ^b   Nahta, R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Breast cancer; HER2; Invasion; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH DIFFERENTIATION FACTOR 15; MITOGEN ACTIVATED PROTEIN KINASE P38; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST TUMOR; CELL PROLIFERATION ASSAY; CLONE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, ERBB-2;

EID: 84893289587     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867320666131119155023     Document Type: Article

References (23)

1. Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; Hanna, W.; Jenkins, R.B.; Mangu, P.B.; Paik, S.; Perez, E.D.; Press, M.F.; Spears, P.A.; Vance, G.H.; Viale, G.; Hayes, D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update. J. Clin. Oncol., 2013, 31(31), 3997-4013.
2. Metro, G.; Mottolese, M.; Fabi, A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin. Pharmacother., 2008, 9(15), 2583-2601.
3. Joshi, J.P.; Brown, N.E.; Griner, S.E.; Nahta, R. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem. Pharmacol., 2011, 82(9), 1090-1099.
4. Bootcov, M.R.; Bauskin, A.R.; Valenzuela, S.M.; Moore, A.G.; Bansal, M.; He, X.Y.; Zhang, H.P.; Donnellan, M.; Mahler, S.; Pryor, K.; Pryor, K.; Walsh, B.J.; Nicholson, R.C.; Fairlie, W.D.; Por, S.B.; Robbins, J.M.; Breit, S.N. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. U S A, 1997, 94(21), 11514-11519. (Pubitemid 27451030)
5. Xu, J.; Kimball, T.R.; Lorenz, J.N.; Brown, D.A.; Bauskin, A.R.; Klevitsky, R.; Hewett, T.E.; Breit, S.N.; Molkentin, J.D. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res., 2006, 98(3), 342-350.
6. Griner, S.E.; Joshi, J.P.; Nahta, R. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochem. Pharmacol., 2013, 85(1), 46-58.
7. Kim, K.K.; Lee, J.J.; Yang, Y.; You, K.H.; Lee, J.H. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis, 2008, 29(4), 704-712. (Pubitemid 351494157)
8. Park, Y.J.; Lee, H.; Lee, J.H. Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep., 2010, 43(2), 91-96.
9. Kim, J.S.; Baek, S.J.; Sali, T.; Eling, T.E. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol. Cancer Ther., 2005, 4(3), 487-493. (Pubitemid 40443934)
10. Yang, H.; Choi, H.J.; Park, S.H.; Kim, J.S.; Moon, Y. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Biochem. Pharmacol., 2009, 78(9), 1205-1213.
11. Brown, D.A.; Ward, R.L.; Buckhaults, P.; Liu, T.; Romans, K.E.; Hawkins, N.J.; Bauskin, A.R.; Kinzler, K.W.; Vogelstein, B.; Breit, S.N. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin. Cancer Res., 2003, 9(7), 2642-2650. (Pubitemid 36842108)
12. Mimeault, M.; Batra, S.K. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell Physiol., 2010, 224(3), 626-635.
13. Roth, P.; Junker, M.; Tritschler, I.; Mittelbronn, M.; Dombrowski, Y.; Breit, S.N.; Tabatabai, G.; Wick, W.; Weller, M.; Wischhusen, J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin. Cancer Res., 2010, 16(15), 3851-3859.
14. Staff, A.C.; Bock, A.J.; Becker, C.; Kempf, T.; Wollert, K.C.; Davidson, B. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol. Oncol., 2010, 118(3), 237-243.
15. Welsh, J.B.; Sapinoso, L.M.; Kern, S.G.; Brown, D.A.; Liu, T.; Bauskin, A.R.; Ward, R.L.; Hawkins, N.J.; Quinn, D.I.; Russell, P.J.; Sutherland, R.L.; Breit, S.N.; Moskaluk, C.A.; Frierson, H.F. Jr.; Hampton, G.M. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. U S A, 2003, 100(6), 3410-3415. (Pubitemid 36356597)
16. Cao, J.; Semenova, M.M.; Solovyan, V.T.; Han, J.; Coffey, E.T.; Courtney, M.J. Distinct requirements for p38alpha and c-Jun Nterminal kinase stress-activated protein kinases in different forms of apoptotic neuronal death. J. Biol. Chem., 2004, 279(34), 35903-35913. (Pubitemid 39100597)
17. Nahta, R.; Takahashi, T.; Ueno, N.T.; Hung, M.C.; Esteva, F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res., 2004, 64(11), 3981-3986. (Pubitemid 38697313)
18. Rowe, D.L.; Ozbay, T.; Bender, L.M.; Nahta, R. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol. Cancer Ther., 2008, 7(7), 1900-1908.
19. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul.,1984, 22, 27-55.
20. Massarweh, S.; Osborne, C.K.; Creighton, C.J.; Qin, L.; Tsimelzon, A.; Huang, S.; Weiss, H.; Rimawi, M.; Schiff, R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res., 2008, 68(3), 826-833. (Pubitemid 351206760)
21. Esteva, F.J.; Sahin, A.A.; Smith, T.L.; Yang, Y.; Pusztai, L.; Nahta, R.; Buchholz, T.A.; Buzdar, A.U.; Hortobagyi, G.N.; Bacus, S.S. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer, 2004, 100(3), 499-506. (Pubitemid 38124766)
22. Antoon, J.W.; Bratton, M.R.; Guillot, L.M.; Wadsworth, S.; Salvo, V.A.; Elliott, S.; McLachlan, J.A.; Burow, M.E. Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am. J. Cancer Res., 2012, 2(4), 446-458.
23. Brunello, A.; Borgato, L.; Basso, U.; Lumachi, F.; Zagonel, V. Targeted approaches to triple-negative breast cancer: current practice and future directions. Curr. Med. Chem., 2013, 20(5), 605-612.